Logo image of VIGL

VIGIL NEUROSCIENCE INC (VIGL) Stock Fundamental Analysis

NASDAQ:VIGL - Nasdaq - US92673K1088 - Common Stock - Currency: USD

8.05  +0.01 (+0.12%)

After market: 8.05 0 (0%)

Fundamental Rating

2

VIGL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. The financial health of VIGL is average, but there are quite some concerns on its profitability. VIGL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VIGL has reported negative net income.
In the past year VIGL has reported a negative cash flow from operations.
In the past 5 years VIGL always reported negative net income.
In the past 5 years VIGL always reported negative operating cash flow.
VIGL Yearly Net Income VS EBIT VS OCF VS FCFVIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -80.94%, VIGL is doing worse than 70.38% of the companies in the same industry.
Looking at the Return On Equity, with a value of -133.18%, VIGL is in line with its industry, outperforming 40.22% of the companies in the same industry.
Industry RankSector Rank
ROA -80.94%
ROE -133.18%
ROIC N/A
ROA(3y)-54.78%
ROA(5y)-63.89%
ROE(3y)-74.94%
ROE(5y)-84.7%
ROIC(3y)N/A
ROIC(5y)N/A
VIGL Yearly ROA, ROE, ROICVIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VIGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VIGL Yearly Profit, Operating, Gross MarginsVIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

VIGL has more shares outstanding than it did 1 year ago.
VIGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VIGL Yearly Shares OutstandingVIGL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
VIGL Yearly Total Debt VS Total AssetsVIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

VIGL has an Altman-Z score of -1.10. This is a bad value and indicates that VIGL is not financially healthy and even has some risk of bankruptcy.
VIGL has a Altman-Z score (-1.10) which is in line with its industry peers.
There is no outstanding debt for VIGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.1
ROIC/WACCN/A
WACCN/A
VIGL Yearly LT Debt VS Equity VS FCFVIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 2.97 indicates that VIGL has no problem at all paying its short term obligations.
VIGL's Current ratio of 2.97 is on the low side compared to the rest of the industry. VIGL is outperformed by 65.53% of its industry peers.
VIGL has a Quick Ratio of 2.97. This indicates that VIGL is financially healthy and has no problem in meeting its short term obligations.
VIGL has a Quick ratio of 2.97. This is in the lower half of the industry: VIGL underperforms 64.09% of its industry peers.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.97
VIGL Yearly Current Assets VS Current LiabilitesVIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

VIGL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.30%.
EPS 1Y (TTM)3.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.25% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.49%
EPS Next 2Y5.54%
EPS Next 3Y-4.66%
EPS Next 5Y18.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VIGL Yearly Revenue VS EstimatesVIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
VIGL Yearly EPS VS EstimatesVIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VIGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VIGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIGL Price Earnings VS Forward Price EarningsVIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIGL Per share dataVIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

VIGL's earnings are expected to decrease with -4.66% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.54%
EPS Next 3Y-4.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VIGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIGIL NEUROSCIENCE INC

NASDAQ:VIGL (7/11/2025, 8:00:02 PM)

After market: 8.05 0 (0%)

8.05

+0.01 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-01 2025-08-01
Inst Owners79.64%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner Change0%
Market Cap375.69M
Analysts52.31
Price Target8.16 (1.37%)
Short Float %0.73%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.88%
Min EPS beat(2)-5.67%
Max EPS beat(2)9.42%
EPS beat(4)3
Avg EPS beat(4)6.62%
Min EPS beat(4)-5.67%
Max EPS beat(4)15.41%
EPS beat(8)6
Avg EPS beat(8)7.04%
EPS beat(12)10
Avg EPS beat(12)8.96%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-48.15%
PT rev (3m)-48.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.82%
EPS NY rev (1m)11.09%
EPS NY rev (3m)19.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.77
P/tB 5.77
EV/EBITDA N/A
EPS(TTM)-2.05
EYN/A
EPS(NY)-1.83
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0
BVpS1.4
TBVpS1.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -80.94%
ROE -133.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.78%
ROA(5y)-63.89%
ROE(3y)-74.94%
ROE(5y)-84.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 62.5%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.97
Altman-Z -1.1
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)440.01%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2%
EPS Next Y20.49%
EPS Next 2Y5.54%
EPS Next 3Y-4.66%
EPS Next 5Y18.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.07%
OCF growth 3YN/A
OCF growth 5YN/A